Structure Therapeutics Inc. American Depositary Shares (GPCR)
Stock · NASDAQ · Health Care
$21.08as of 10/16/2026
Price chart
Active signals
GPCR Signal Track Record
How signals performed across all stocks →What GPCR's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 26 | -5.4% | 35% | September 24, 2026 |
| Bollinger Band Breakout | 14 | -3.3% | 43% | August 10, 2026 |
| Bollinger Band Breakdown | 12 | -0.7% | 50% | August 31, 2026 |
| 200-Day Moving Average TouchActive now | 8 | -3.9% | 38% | August 6, 2026 |
| Any 20-session window (baseline) | -3.4% | 43% |
Computed by MarketWall from daily closing prices since November 17, 2023. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About GPCR
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweig…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 281
- Website
- structuretx.com/
Fundamentals
- 1-day range
- $27.57$29.25
- Market cap
- $3.74B
- P/E (trailing)
- —
- P/E (forward)
- -13.10
- EPS (trailing)
- $-1.04
- Dividend yield
- —
- Beta
- -1.50
- Avg. volume
- 920.6K
Forecasts
15 analyst ratings
Structure Therapeutics Inc. American Depositary Shares Competitors
Chosen by industry and closest market cap.
- GPCRStructure Therapeutics Inc. American Depositary Shares$21.08▼ 5.00%Market cap $3.74BP/E —$25.59$94.9
- ELVNEnliven Therapeutics Inc. Common Stock$37.32▼ 5.11%Market cap $3.67BP/E —$14.79$62.32
- GMABGenmab A/S ADS$37▼ 2.17%Market cap $3.83BP/E 26.41$1,512$2,369
- TLXTelix Pharmaceuticals Limited American Depositary Shares$10.69▲ 1.14%Market cap $3.60BP/E —$6.28$13.11
- VKTXViking Therapeutics Inc. Common Stock$25.17▼ 8.04%Market cap $3.88BP/E —$25.77$43.15
- LEGNLegend Biotech Corporation American Depositary Shares$18.48▼ 6.67%Market cap $3.58BP/E —$16.24$37.5
- RCUSArcus Biosciences Inc. Common Stock$22.12▼ 3.07%Market cap $3.56BP/E —$15.38$31.74
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| GPCR Structure Therapeutics Inc. American Depositary Shares | $3.74B | — | $21.08 | ▼ 5.00% | $25.59$94.9 |
| ELVN Enliven Therapeutics Inc. Common Stock | $3.67B | — | $37.32 | ▼ 5.11% | $14.79$62.32 |
| GMAB Genmab A/S ADS | $3.83B | 26.41 | $37 | ▼ 2.17% | $1,512$2,369 |
| TLX Telix Pharmaceuticals Limited American Depositary Shares | $3.60B | — | $10.69 | ▲ 1.14% | $6.28$13.11 |
| VKTX Viking Therapeutics Inc. Common Stock | $3.88B | — | $25.17 | ▼ 8.04% | $25.77$43.15 |
| LEGN Legend Biotech Corporation American Depositary Shares | $3.58B | — | $18.48 | ▼ 6.67% | $16.24$37.5 |
| RCUS Arcus Biosciences Inc. Common Stock | $3.56B | — | $22.12 | ▼ 3.07% | $15.38$31.74 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Can Novo's Licensing Strategy Build Its Next Wave of Oral Medicines?Yahoo · 9/30/2026
- Can Novo's Rare Disease Pipeline Add a New Growth Pillar Beyond GLP-1?Yahoo · 9/23/2026
- Viking Soars Alone as Obesity Complex Shrugs at Strong GLP-1 ResultsYahoo · 9/22/2026
- Structure Therapeutics (GPCR) Gains Fresh Obesity Trial Backing Following Data That Keeps Valuation In FocusYahoo · 9/22/2026
- VKTX, GPCR, ALT Stocks Rise: Novo Nordisk Signals Bigger M&A As It Chases Over 5 ‘Multi-Blockbusters’Yahoo · 9/22/2026
- LLY Stock Down Around 7% in a Month: Buy the Dip or Stay Cautious?Yahoo · 9/17/2026
- Novo Falls 5% in a Week: How Should Investors Approach the Stock Now?Yahoo · 9/17/2026
- Structure Therapeutics Inc. (GPCR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeekingAlpha · 9/16/2026
Insider Activity
Insider Actions →- Crespo Blas Coll · September 21, 2026 · Sale4.0K @ $36.15
- Crespo Blas Coll · September 21, 2026 · Conversion4.0K
- Crespo Blas Coll · September 21, 2026 · Conversion12.0K
- Crespo Blas Coll · September 18, 2026 · Tax Withholding10.6K @ $11.67
- Xichen Lin · September 1, 2026 · Sale100 @ $47.83
- Xichen Lin · September 1, 2026 · Sale4.5K @ $47.2
- Xichen Lin · September 1, 2026 · Sale1.3K @ $45.86
- Xichen Lin · September 1, 2026 · Conversion5.9K
- Xichen Lin · September 1, 2026 · Option Exercise17.8K @ $0.34
- Xichen Lin · September 1, 2026 · Conversion17.8K
- Xichen Lin · August 18, 2026 · Sale400 @ $55.05
- Xichen Lin · August 18, 2026 · Sale519 @ $54.2
- Xichen Lin · August 18, 2026 · Sale3.0K @ $53.13
- Xichen Lin · August 18, 2026 · Conversion3.9K
- Xichen Lin · August 18, 2026 · Option Exercise11.8K @ $0.34
Institutional Ownership
March 31, 2026
- Total shares held
- 67.34M
- Total value held
- $3.15B
- Institutional holders
- 195
- Unknown8.40M
- Unknown7.26M
- Unknown6.56M
- Unknown5.35M
- Unknown4.28M
- Unknown3.46M
- Unknown2.31M
- Unknown2.00M
- Unknown1.75M
- Unknown1.58M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
LLY Stock Dip News Unrelated to GPCR
Recent headlines focus on Eli Lilly (LLY) stock performance, which does not provide specific news about Structure Therapeutics (GPCR). While GPCR technical indicators show extreme oversold conditions, the provided news articles do not contain company-specific updates or developments for this symbol.
LLY Stock Dip News Unrelated to GPCR. Recent headlines focus on Eli Lilly (LLY) stock performance, which does not provide specific news about Structure Therapeutics (GPCR). While GPCR technical indicators show extreme oversold conditions, the provided news articles do not contain company-specific updates or developments for this symbol.